Roche’s stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant, did not meet expectations in its recent trial.
The stock saw a modest recovery during the morning, trading down 4.6% to 325.80 Swiss francs, marking a two-month low. The late-stage trial failed to demonstrate that giredestrant, in combination with Pfizer’s Ibrance, was more effective than standard hormonal therapies.
Despite the setback, analysts perceive potential. Barclays’ James Gordon suggests the share drop presents a buying opportunity, with market opportunities for add-on treatments not fully realized. However, Jefferies analyst Michael Leuchten anticipates the news will reverse previous positive momentum.
(With inputs from agencies.)